Newton: Transports ...
Health Care: Drugs
EpiCept Corporation (EPCT: OTC)
$0.27 0.01 | 3.45%
02/08/12 - 03:03 PM ET
156.39K / 47.00K
Vol / Avg. Vol:0.28 / 0.26
Open / Prev. Close:0.26 - 0.28
Today's Range:0.25 - 0.79
52 Wk Range:-60.92%
Performance YTD:TheStreet Rating:
Portfolios with EPCT
- Portfolio NameUser Type
- Usergdean1
- Usernoneya Portfolio 1
- UserBAMAITAL
- UserPANTERA GROUP 146
- Userunlikely
- Useryinghcho Portfolio 1
- Usersmall caps with good futures
- UserBENITRANS DH
- Userindo
- UserEmerging Cancer
Latest EPCT Headlines from TheStreet
- Biotech Sector Weekly Rewind 12.11.10 | 08:12 am
- Bankruptcy Watch: Stocks Under $5 09.16.10 | 06:09 am
- Stock Offerings: EpiCept 06.28.10 | 09:06 am
- EpiCept 3Q Loss Narrows On Lower Costs 11.10.09 | 03:11 pm
- Biotech Stock Mailbag: Cyclacel Pharma 09.18.09 | 07:09 am
- Biotech Mailbag: Study Boosts ImmunoGen 10.17.08 | 11:10 am
- Thursday's Health Winners & Losers 08.06.07 | 09:08 pm
- Friday's Small-Cap Winners & Losers 06.29.07 | 02:06 pm
- Friday's Health Winners & Losers 06.15.07 | 04:06 pm
- Studies Pep Up EpiCept 05.02.07 | 09:05 pm
Press Releases for EPCT
- EpiCept To Present At The 14th Annual BIO CEO & Investor Conference - Business Wire 02.08.12 | 05:02 pm
- EpiCept Files For AmiKet™ Fast Track Designation - Business Wire 02.07.12 | 12:02 am
- EpiCept Corporation Confirms Engagement Of SunTrust Robinson Humphrey To Include Evaluation Of Potential Sale Transactions - Business Wire 01.24.12 | 01:01 pm
- EpiCept Corporation Receives Finalized FDA Guidance For AmiKet™ Phase III CIPN Program And Regulatory Strategy - Business Wire 01.23.12 | 12:01 am
- EpiCept Corporation Engages SunTrust Robinson Humphrey To Advise On Strategy To Maximize AmiKet™ Potential - Business Wire 01.09.12 | 12:01 am
- EpiCept To Present At Two Upcoming Industry Conferences - Business Wire 01.05.12 | 05:01 pm
- EpiCept Corporation Appoints Alan W. Dunton, M.D. Non-Executive Chairman Of The Board - Business Wire 01.05.12 | 12:01 am
- EpiCept Corporation Receives FDA Permission To Initiate AmiKet™ Phase III Clinical Development - Business Wire 12.23.11 | 12:12 am
- EpiCept Provides Update On Ceplene® Manufacturing At Ben Venue Laboratories - Business Wire 12.21.11 | 12:12 am
- EpiCept To Present At The 22nd Annual Wall Street Institutional Investor Conference - Business Wire 11.30.11 | 05:11 pm
Partner Headlines for EPCT
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
- Zacks Maintains Outperform on EpiCept - Benzinga 08.16.11 | 09:08 am
- EpiCept's Promising Leukemia Drug: A Buying Opportunity? - Seeking Alpha 10.15.10 | 02:10 pm
- China Analyst: 10 Pharma Stocks With Highest Growth Potential - Seeking Alpha 10.08.10 | 06:10 am
- FDA Committee Rejects Expanded Use of Jazz Drug on Abuse Concerns: Biotech's Latest Failures - Seeking Alpha 08.30.10 | 08:08 am
- Tech Stocks Fly, Pharma Stocks Cry! (DELL, HPQ, PAR, CML, CVLT, ISLN, TPL, JAZZ, EPCT, CPIX) - Benzinga 08.23.10 | 01:08 pm
- Epicept: Good Play in Light of Recent Developments - Seeking Alpha 06.02.10 | 03:06 am
- Three Promising Small-Cap Cancer Plays - Seeking Alpha 05.17.10 | 08:05 am
